Research ArticleCancer

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia

See allHide authors and affiliations

Science Translational Medicine  03 Sep 2014:
Vol. 6, Issue 252, pp. 252ra121
DOI: 10.1126/scitranslmed.3009073
PDF Container

Stay Connected to Science Translational Medicine